Emergent Biosolutions announced the development of two plasma-derived product candidates for the treatment and prevention of COVID-19. This announcement, in conjunction with yesterday’s, demonstrates our commitment to combating this pandemic in a comprehensive, multi-faceted manner. Thank you Laura Saward and our Therapeutics Business Unit for pursuing opportunities to live our mission – to protect and enhance life!
Robert G. Kramer Sr., President and CEO at Emergent BioSolutions, stated, “As a company focused on public health threats, we are committed to responding to this novel coronavirus and will use our broad capabilities and platforms to advance solutions. On the heels of our collaboration with an industry partner to develop an experimental vaccine candidate for clinical testing, we are pleased to leverage our existing infrastructure to help expedite development of our product candidates for COVID-19, founded on our decades of experience in hyperimmune manufacturing.”